Claritas Pharmaceuticals Stock Performance
| CLAZF Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Claritas Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Claritas Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Claritas Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 32 K | |
| Total Cashflows From Investing Activities | 2000.00 |
Claritas |
Claritas Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Claritas Pharmaceuticals on September 28, 2025 and sell it today you would earn a total of 0.00 from holding Claritas Pharmaceuticals or generate 0.0% return on investment over 90 days. Claritas Pharmaceuticals is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Claritas, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Claritas Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Claritas Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Claritas Pharmaceuticals, and traders can use it to determine the average amount a Claritas Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CLAZF |
Based on monthly moving average Claritas Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Claritas Pharmaceuticals by adding Claritas Pharmaceuticals to a well-diversified portfolio.
Claritas Pharmaceuticals Fundamentals Growth
Claritas Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Claritas Pharmaceuticals, and Claritas Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Claritas Pink Sheet performance.
| Return On Equity | 0.65 | |||
| Return On Asset | 0.0277 | |||
| Current Valuation | 948.45 K | |||
| Shares Outstanding | 36.59 M | |||
| Price To Earning | 0.04 X | |||
| Price To Book | 0.12 X | |||
| EBITDA | (449 K) | |||
| Cash And Equivalents | 2 K | |||
| Total Debt | 538 K | |||
| Debt To Equity | 0.16 % | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (309 K) | |||
| Earnings Per Share | 0.15 X | |||
| Total Asset | 10.45 M | |||
About Claritas Pharmaceuticals Performance
By analyzing Claritas Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Claritas Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Claritas Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Claritas Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was founded in 2014 and is headquartered in San Rafael, California. Claritas Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Claritas Pharmaceuticals performance evaluation
Checking the ongoing alerts about Claritas Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Claritas Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Claritas Pharmaceuticals generated a negative expected return over the last 90 days | |
| Claritas Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Claritas Pharmaceuticals has accumulated about 2 K in cash with (309 K) of positive cash flow from operations. |
- Analyzing Claritas Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Claritas Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Claritas Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Claritas Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Claritas Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Claritas Pharmaceuticals' pink sheet. These opinions can provide insight into Claritas Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Claritas Pink Sheet analysis
When running Claritas Pharmaceuticals' price analysis, check to measure Claritas Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Claritas Pharmaceuticals is operating at the current time. Most of Claritas Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Claritas Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Claritas Pharmaceuticals' price. Additionally, you may evaluate how the addition of Claritas Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |